Upadacitinib monotherapy effective in refractory RA

Rheumatologists now have many choices for the treatment of such patients, expert says

Monotherapy with the JAK1-selective inhibitor upadacitinib is effective in patients with active rheumatoid arthritis who have an inadequate response to methotrexate, according to results of a phase 3 trial.


Researchers from 24 countries compared upadacitinib monotherapy to continuing methotrexate treatment in a randomised controlled trial of 648 rheumatoid arthritis patients with an inadequate response to methotrexate.

One of the primary endpoints of the SELECT-MONOTHERAPY trial was the percentage of patients who achieved a 20% improvement in the